Dopamine agonists and the risk of cardiac-valve regurgitation.

By R. Schade, F. Andersohn, S. Suissa, W. Haverkamp, E. Garbe. New England Journal of Medicine, 2007

649 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Neurology

View Paper: https://www.semanticscholar.org/paper/0ae37e080492fd2ac77a685293ba97154bd42640

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Victor M. Montori

Citations in the corpus

• Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. (2011, background): “Patients with Parkinson’s disease receiving at least 3 mg of cabergoline daily are at risk for moderate to severe cardiac valve regurgitation (96, 97).”
• Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. (2008, background): “However, more data are required not only for efficacy but also to address the long-term safety of cabergoline in these patients (84, 85).”